]>
IRCT201012055280N2 IRCT 2011-02-18 Mashhad University of Medical Scinces Therapeutic Efficacy of Oxcarbazepine and Sodium Valproate in Acute Mania Therapeutic Efficacy of Oxcarbazepine and Sodium Valproate in Acute Mania 2009-07-04 anticipated 48 Complete https://irct.ir/trial/5628 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 acute mania. Intervention 1: In the first group, during the 2 weeks titration phase, the Oxcarpazepine was started by 300 mg and increased every 2 days to a maximum dose of 900 to 2400 mg per days or the highest tolerated dose. Intervention 2: In the second group, Na Valporate was initiated by 600 mg/day and increased to a 20-36 mg/day or the highest tolerated dose for patients.
public Dr. Ali Talaei
Ibn-e-Sina psychiatric Hospital, Horre Ameli avenue, Boo Ali square
Mashhad Iran (Islamic Republic of) +98 51 3711 2540 talaeia@mums.ac.ir , alitalaei@gmail.com Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, Mashhad University of Medic scientific Dr Atefeh Soltanifar
Ibn-e-Sina psychiatric Hospital, Horre Ameli avenue, Boo Ali square
Mashhad Iran (Islamic Republic of) +98 51 1711 2721 soltanifara@mums.ac.ir Psychiatry and Behavioral Sciences Research Center, Ibn-e-sina Hospital Mashhad University of Medica Iran (Islamic Republic of) For eligibility in the study patients had to be 18 to 60 years of age and with DSM- IV- TR axis I diagnosis of BMD-I in acute manic episode. Exclusion criteria included a primary diagnosis of Schizophrenia, delirium, anorexia nervosa, bulimia, autism, substance abuse, mental retardation and ADHD in recent 3 months. Other exclusion criteria were a history of epilepsy, a history of psychogenic polydipsia, a history of symptomatic hyponatremia and patients who were taking other antimanic medications during the study prior or within one week before it. Patients were required to be free of psychotropic drugs with exceptions of diphenhydramin or lorazapam for control of agitation and aggression. Risperidone 2-4 mg/day was prescribed for all of patients. 18 years 60 years Both F30.1 Mania without psychotic symptoms Treatment - Drugs Treatment - Drugs In the first group, during the 2 weeks titration phase, the Oxcarpazepine was started by 300 mg and increased every 2 days to a maximum dose of 900 to 2400 mg per days or the highest tolerated dose. In the second group, Na Valporate was initiated by 600 mg/day and increased to a 20-36 mg/day or the highest tolerated dose for patients. Change of mood. Timepoint: base line,weeks 3,6. Method of measurement: Young Mania rating scale. Clinical Global Impression Scale. Timepoint: base line ,weeks 3 and 6. Method of measurement: change of scores. Mashhad University of Medical Scinces Approved 2009-06-30 Ethics Committee of Mashhad University of Medical Sciences Daneshgah street, Ghoreishi building Mashhad Iran (Islamic Republic of)